ClinicalTrials.gg
Active, not recruitingNCT05371080Updated Jan 18, 2024

A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults

A Phase 3 interventional study of HZ/su vaccine in Herpes Zoster, sponsored by GlaxoSmithKline. Active, not recruiting at 107 sites in 18 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2024-01-18.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
3,038
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 46 studies testing shingrix in Herpes Zoster — 8 open to participants now, 11 under way, 3 of them phase 3. shingrix · Herpes Zoster.

Planned enrollment
7th of 46
3,038 · median 239
Started
2022
with 2 others
Phase 3
22 of 46
2 open now
Primary completion
2027-08
later than 6 of 10 live
Registered
35th of 46
by date
Lead sponsor
26 of 46
GlaxoSmithKline

Among the 46 studies testing shingrix in Herpes Zoster, this one is the 7th largest by planned enrollment, is one of 3 that started in 2022, is one of 22 in phase 3, reaches primary completion later than 6 of the 10 other live ones, and was the 35th registered.

Herpes Zoster

299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.

Browse Herpes Zoster studies →

Open to participants now

8 of the 46 studies testing shingrix in Herpes Zoster are open now, in 5 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About shingrix

shingrix: first FDA approval 2017 (Shingrix). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing shingrix in Herpes Zoster, or all of them as a file.
02

Study summary

The purpose of the current ZOSTER-101 long-term follow-up (LTFU) study of ZOSTER-049 (NCT02723773) study, an extension of ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) primary studies, is to assess the long-term vaccine efficacy (VE) against Herpes Zoster (HZ) (approximately 11-15 years post primary vaccination in ZOSTER-006/022 studies), persistence of immunogenicity and safety of GSK's Herpes Zoster subunit (HZ/su) vaccine in older adults. The persistence of immunogenicity and safety of 1 or 2 additional doses (0, 2-month schedule) of HZ/su vaccine administered to a small group of participants in ZOSTER-049 study (approximately 5 years after the initial vaccination in ZOSTER-006/022 studies) will also be assessed.

03

Conditions studied

  • Herpes Zoster

Browse trials for

Keywords

  • Shingles
  • Herpes Zoster subunit vaccine
  • Recombinant Zoster Vaccine (RZV)
  • Long-term follow-up study
  • Long-term vaccine efficacy
  • Prophylactic efficacy
  • Safety
  • Persistence of immune response
  • Older adults
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants and participant's caregiver, who, in the opinion of the investigator, can and are willing to comply with the requirements of the protocol.
  • Written or witnessed/thumb printed obtained from the participant prior to performance of any study-specific procedure.
  • Medically stable participants as established by medical history and clinical examination before entering into the study.
  • Participants who completed ZOSTER-049 study (following at least 1 dose of HZ/su in ZOSTER-006/022 studies).

Exclusion criteria

Exclusion Criteria:

Medical conditions

  • Any clinical condition that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the study.

Prior/Concomitant therapy

  • Use of any or non-registered product (drug, vaccine or medical device) for the treatment of HZ or Varicella Zoster Virus (VZV) infection at the time of enrolment or their planned use during the study period.
  • Previous vaccination against VZV or HZ and/or planned administration during the study of a VZV or HZ vaccine (including an investigational or non-registered vaccine other than HZ/su administered in studies ZOSTER-006/022 or ZOSTER-049).

Prior/Concurrent clinical study experience

  • Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational intervention (drug/invasive medical device) for the prevention and/or treatment of HZ or VZV and which may have a possible activity against VZV.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Factorial assignment
Masking
None (open label)
Enrollment
3,038 participants (estimated)

Study arms

  • Other
    LTFU Group

    Participants who received at least one dose of the HZ/su vaccine in the ZOSTER-006/022 primary studies and are followed for long-term vaccine efficacy and safety in the current ZOSTER-101 study.

    Biological: HZ/su vaccine

  • Other
    1-Additional Dose Group

    Participants who received two doses of the HZ/su vaccine in the ZOSTER-006/022 primary studies and one additional dose of the HZ/su vaccine in the ZOSTER-049 study and are followed for persistence of immunogenicity and safety in the current ZOSTER-101 study.

    Biological: HZ/su vaccine

  • Other
    Revaccination Group

    Participants who received two doses of the HZ/su vaccine in the ZOSTER-006/022 primary studies and two additional doses of the HZ/su vaccine in the ZOSTER-049 study and are followed for persistence of immunogenicity and safety in the current ZOSTER-101 study.

    Biological: HZ/su vaccine

  • Other
    Control Group

    Participants who received two doses of the HZ/su vaccine in the ZOSTER-006/022 primary studies and no additional doses of the HZ/su vaccine in the ZOSTER-049 study, but who served as a control for the two groups that received 1 or 2 additional doses of HZ/su (1-Additional Dose and Revaccination groups). In the current ZOSTER-101 study, this Control group is used in the evaluation of the long-term vaccine efficacy, safety and as a control for persistence of immunogenicity to additional doses administered in ZOSTER-049 study.

    Biological: HZ/su vaccine

Interventions

  • BiologicalHZ/su vaccine

    Drug page: Shingrix

    No study intervention is administered in this extension study. Participants received the HZ/su vaccine administered in the ZOSTER-049 (NCT02723773), ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) primary studies. In order to assess the persistence of immune responses, participants provide blood samples at Day 1 and yearly from Month 12 until Month 48 in the current ZOSTER-101 study, according to their study group assignment. In case of a suspected HZ case diagnosis in any of the participants, clinical specimens from HZ lesions (3 replicate samples, collected on the same day, per participant) are collected to confirm the diagnosis of HZ by Polymerase Chain Reaction (PCR)

06

What researchers measure

Primary outcomes

  1. Number of participants in LTFU and Control groups with confirmed HZ cases

    A suspected case of HZ is defined as new unilateral rash accompanied by pain (broadly defined to include allodynia, pruritus or other sensations) and no alternative diagnosis. A suspected case of HZ can be confirmed in two ways: * By PCR; * By the HZ Ascertainment Committee (HZAC).

    Time frame: During the total duration of ZOSTER-101 study (Day 1 through Month 48)

Secondary outcomes

  1. Number of participants in LTFU and Control groups with confirmed HZ cases

    A suspected case of HZ is defined as new unilateral rash accompanied by pain (broadly defined to include allodynia, pruritus or other sensations) and no alternative diagnosis. A suspected case of HZ can be confirmed in two ways: * By PCR; * By the HZAC.

    Time frame: From 1-month post-Dose 2 in the ZOSTER-006/022 studies until the end of the ZOSTER-101 study at Month 48

  2. Anti-glycoprotein E (gE) antibody concentrations

    Anti-gE antibody concentrations are expressed as geometric mean concentrations (GMCs), as determined by enzyme-linked immunosorbent assay (ELISA).

    Time frame: At Day 1, Months 12, 24, 36 and 48 in the ZOSTER-101 study

  3. Frequency of gE-specific Cluster of Differentiation (CD)4+ T-cells secreting at least two activation markers from among IFN-γ, IL-2, TNF-α, CD40L

    Time frame: At Day 1, Months 12, 24, 36 and 48 in the ZOSTER-101 study

  4. Percentage of participants with serious adverse events (SAEs) causally related to the study intervention

    An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, or results in disability/incapacity. Relationship between study intervention and the occurrence of SAEs is assessed by the investigator using clinical judgement.

    Time frame: During the total duration of the ZOSTER-101 study (Day 1 through Month 48)

  5. Percentage of participants with potential immune-mediated diseases (pIMDs) (serious and non-serious) causally related to the study intervention

    pIMDs are a subset of adverse events of special interest that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology. A serious pIMD is any pIMD that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, or results in disability/incapacity. Relationship between study intervention and the occurrence of pIMDs is assessed by the investigator using clinical judgement.

    Time frame: During the total duration of the ZOSTER-101 study (Day 1 through Month 48)

  6. Percentage of participants with HZ-related complications of confirmed HZ

    A suspected case of HZ is defined as new unilateral rash accompanied by pain (broadly defined to include allodynia, pruritus or other sensations) and no alternative diagnosis. A suspected case of HZ can be confirmed in two ways: * By PCR; * By the HZAC. HZ complications are the following: post-herpetic neuralgia, HZ vasculitis, disseminated disease, ophthalmic disease, neurologic disease, visceral disease or stroke A.

    Time frame: During the total duration of the ZOSTER-101 study (Day 1 through Month 48)

07

Study locations

107 sites
  • GSK Investigational Site
    Phoenix, Arizona 85020, United States
  • GSK Investigational Site
    Elkridge, Maryland 21075, United States
  • GSK Investigational Site
    Charlotte, North Carolina 28209, United States
  • GSK Investigational Site
    Hickory, North Carolina 28601, United States
  • GSK Investigational Site
    Pittsburgh, Pennsylvania 15236, United States
  • GSK Investigational Site
    Bristol, Tennessee 37620, United States
  • GSK Investigational Site
    San Antonio, Texas 78229, United States
  • GSK Investigational Site
    Salt Lake City, Utah 84106, United States
  • GSK Investigational Site
    Warrawong, New South Wales 2502, Australia
  • GSK Investigational Site
    Westmead, New South Wales 2145, Australia
  • GSK Investigational Site
    Geelong, Victoria 3220, Australia
  • GSK Investigational Site
    Belo Horizonte, Minas Gerais 30150-320, Brazil
  • GSK Investigational Site
    Curitiba, Paraná 80069-900, Brazil
  • GSK Investigational Site
    São Paulo, 04266-010, Brazil
  • GSK Investigational Site
    São Paulo, 05403-000, Brazil
  • GSK Investigational Site
    Vancouver, British Columbia V5Z 1M9, Canada
  • GSK Investigational Site
    Victoria, British Columbia V8R 6R3, Canada
  • GSK Investigational Site
    Halifax, Nova Scotia B3K 6R8, Canada
  • GSK Investigational Site
    Truro, Nova Scotia B2N1L2, Canada
  • GSK Investigational Site
    Toronto, Ontario M4S 1Y2, Canada
  • GSK Investigational Site
    Toronto, Ontario M9W 4L6, Canada
  • GSK Investigational Site
    Mirabel, Quebec J7J 2K8, Canada
  • GSK Investigational Site
    Québec City, Quebec G1E 7G9, Canada
  • GSK Investigational Site
    Sherbrooke, Quebec J1J 2G2, Canada
  • GSK Investigational Site
    Quebec, G1W 4R4, Canada
  • GSK Investigational Site
    Brno, 612 00, Czechia
  • GSK Investigational Site
    Ceske Budejovice, 370 05, Czechia
  • GSK Investigational Site
    Hradec Kralove, 500 05, Czechia
  • GSK Investigational Site
    Tallinn, 13619, Estonia
  • GSK Investigational Site
    Tartu, 50106, Estonia
  • GSK Investigational Site
    Espoo, 02230, Finland
  • GSK Investigational Site
    Helsinki, 00100, Finland
  • GSK Investigational Site
    Helsinki, 00930, Finland
  • GSK Investigational Site
    Jarvenpaa, 04400, Finland
  • GSK Investigational Site
    Kokkola, 67100, Finland
  • GSK Investigational Site
    Oulu, 90220, Finland
  • GSK Investigational Site
    Pori, 28100, Finland
  • GSK Investigational Site
    Seinajoki, 60100, Finland
  • GSK Investigational Site
    Tampere, 33100, Finland
  • GSK Investigational Site
    Turku, 20520, Finland
  • GSK Investigational Site
    Angers, 49000, France
  • GSK Investigational Site
    Clermont-Ferrand, 63003, France
  • GSK Investigational Site
    Laval, 53000, France
  • GSK Investigational Site
    Murs Erigne, 49610, France
  • GSK Investigational Site
    Rosiers d'Egletons, 19300, France
  • GSK Investigational Site
    Wangen, Baden-Wuerttemberg 88239, Germany
  • GSK Investigational Site
    Weinheim, Baden-Wuerttemberg 69469, Germany
  • GSK Investigational Site
    Rednitzhembach, Bayern 91126, Germany
  • GSK Investigational Site
    Wallerfing, Bayern 94574, Germany
  • GSK Investigational Site
    Floersheim, Hessen 65439, Germany
  • GSK Investigational Site
    Essen, Nordrhein-Westfalen 45355, Germany
  • GSK Investigational Site
    Essen, Nordrhein-Westfalen 45359, Germany
  • GSK Investigational Site
    Goch, Nordrhein-Westfalen 47574, Germany
  • GSK Investigational Site
    Koeln, Nordrhein-Westfalen 51069, Germany
  • GSK Investigational Site
    Witten, Nordrhein-Westfalen 58455, Germany
  • GSK Investigational Site
    Mainz, Rheinland-Pfalz 55116, Germany
  • GSK Investigational Site
    Magdeburg, Sachsen-Anhalt 39112, Germany
  • GSK Investigational Site
    Dresden, Sachsen 01097, Germany
  • GSK Investigational Site
    Freiberg, Sachsen 09599, Germany
  • GSK Investigational Site
    Berlin, 10787, Germany
  • GSK Investigational Site
    Hamburg, 22143, Germany
  • GSK Investigational Site
    Hamburg, 22415, Germany
  • GSK Investigational Site
    Shatin, 000000, Hong Kong
  • GSK Investigational Site
    Genova, Liguria 16132, Italy
  • GSK Investigational Site
    Milano, Lombardia 20127, Italy
  • GSK Investigational Site
    Fukuoka, 810-0021, Japan
  • GSK Investigational Site
    Fukuoka, 812-0025, Japan
  • GSK Investigational Site
    Fukuoka, 813-8588, Japan
  • GSK Investigational Site
    Fukuoka, 816-0864, Japan
  • GSK Investigational Site
    Kanagawa, 224-8503, Japan
  • GSK Investigational Site
    Tokyo, 142-8666, Japan
  • GSK Investigational Site
    Ansan, 425-707, Korea, Republic of
  • GSK Investigational Site
    Bucheon-si,, 420-767, Korea, Republic of
  • GSK Investigational Site
    Incheon, 400-711, Korea, Republic of
  • GSK Investigational Site
    Kangwon-do, 220-701, Korea, Republic of
  • GSK Investigational Site
    Seoul, 150-950, Korea, Republic of
  • GSK Investigational Site
    Seoul, 152-703, Korea, Republic of
  • GSK Investigational Site
    Durango, 34000, Mexico
  • GSK Investigational Site
    Balenyà (Barcelona), 08550, Spain
  • GSK Investigational Site
    Barcelona, 08035, Spain
  • GSK Investigational Site
    Barcelona, 8025, Spain
  • GSK Investigational Site
    Centelles (Barcelona), 08540, Spain
  • GSK Investigational Site
    La Roca del Vallès, 08430, Spain
  • GSK Investigational Site
    Madrid, 28046, Spain
  • GSK Investigational Site
    Majadahonda( Madrid, 28222, Spain
  • GSK Investigational Site
    Marid, 28040, Spain
  • GSK Investigational Site
    Peralada( Girona), 17491, Spain
  • GSK Investigational Site
    Valencia, 46020, Spain
  • GSK Investigational Site
    Vic, 28500, Spain
  • GSK Investigational Site
    Borås, SE-506 30, Sweden
  • GSK Investigational Site
    Göteborg, SE-413 45, Sweden
  • GSK Investigational Site
    Karlskrona, Sweden
  • GSK Investigational Site
    Linköping, SE-58758, Sweden
  • GSK Investigational Site
    Malmö, SE-211 52, Sweden
  • GSK Investigational Site
    Stockholm, Sweden
  • GSK Investigational Site
    Upplands Väsby, SE-194 61, Sweden
  • GSK Investigational Site
    Uppsala, SE-751 85, Sweden
  • GSK Investigational Site
    Örebro, SE-703 62, Sweden
  • GSK Investigational Site
    Taichung, 40447, Taiwan
  • GSK Investigational Site
    Taipei, 10002, Taiwan

Showing the first 100 of 107 sites across 18 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, a key secondary endpoints and safety data of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2022 (actual). Primary completion is estimated for Aug 2027, 60 months after the start.

Of 33 industry-sponsored phase 3 interventional studies under Herpes Zoster, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 45. This study's planned 60 months is above that.

Counting every sponsor, half of 40 studies reached it within 16 months; a quarter within 10 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2022
First posted
May 12, 2022
StartActual
Aug 10, 2022
Primary completionEst.
Aug 23, 2027
CompletionEst.
Aug 23, 2027
Last update
Jan 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05371080
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
May 12, 2022
Start date
Aug 10, 2022
Primary completion
Aug 23, 2027 (estimated)
Completion
Aug 23, 2027 (estimated)
Last update
Jan 18, 2024

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Shingrix

Start the discussion